Failures of major anti-TIGIT antibody candidates, following promising early results, reveal challenges in immuno-oncology development. Key phase 3 trials halted due to lack of efficacy underscore the risks of overextension in targeting immune checkpoints. The cumulative $6 billion investment reflects high market stakes and hard lessons on translating early immunotherapy promise into clinical success.